2024 |
IQVIA Holdings Inc
|
Lead Independent Director |
411.2 K |
11.9 % |
2024 |
Intellia Therapeutics Inc
|
Director, President and Chief Executive Officer |
- |
- |
2023 |
IQVIA Holdings Inc
|
Lead Independent Director |
367.4 K |
1.4 % |
2023 |
Intellia Therapeutics Inc
|
Director, President and Chief Executive Officer |
- |
- |
2022 |
IQVIA Holdings Inc
|
Lead Independent Director |
362.5 K |
1.4 % |
2022 |
Intellia Therapeutics Inc
|
Director, President and Chief Executive Officer |
- |
- |
2021 |
IQVIA Holdings Inc
|
Lead Independent Director |
357.5 K |
2.3 % |
2021 |
Intellia Therapeutics Inc
|
Director, President and Chief Executive Officer |
- |
- |
2020 |
IQVIA Holdings Inc
|
Lead Independent Director |
349.6 K |
-2.2 % |
2020 |
Intellia Therapeutics Inc
|
Director, President and Chief Executive Officer |
- |
- |
2019 |
IQVIA Holdings Inc
|
Lead Independent Director |
357.4 K |
9.8 % |
2019 |
Intellia Therapeutics Inc
|
Director, President and Chief Executive Officer |
- |
- |
2018 |
IQVIA Holdings Inc
|
Lead Independent Director |
325.6 K |
3.4 % |
2018 |
Chimerix Inc
|
- |
62.6 K |
-47.1 % |
2018 |
Chimerix Inc
|
Independent Director |
- |
- |
2018 |
Intellia Therapeutics Inc
|
Director, President and Chief Executive Officer |
- |
- |
2017 |
IQVIA Holdings Inc
|
Independent Director |
314.9 K |
12.3 % |
2017 |
Chimerix Inc
|
Independent Director |
118.3 K |
86.7 % |
2017 |
Intellia Therapeutics Inc
|
President, Chief Executive Officer and Director |
- |
- |
2016 |
IQVIA Holdings Inc
|
Independent Director |
280.5 K |
-35.3 % |
2016 |
Chimerix Inc
|
Independent Director |
63.4 K |
-76.0 % |
2016 |
Intellia Therapeutics Inc
|
Executive Vice President, Research and Development |
- |
- |
2015 |
IQVIA Holdings Inc
|
Independent Director |
433.4 K |
- |
2015 |
Chimerix Inc
|
Independent Director |
263.8 K |
-35.1 % |
2015 |
Intellia Therapeutics Inc
|
Chief Medical Officer and Director |
- |
- |
2014 |
Chimerix Inc
|
Independent Director |
406.5 K |
- |
2014 |
IQVIA Holdings Inc
|
Independent Director |
- |
- |